Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Internal Medicine
•
Gastroenterology
•
Allergy & Immunology
•
Mast Cell Disorders
•
Gastrointestinal Functional & Motility Disorders
•
General Gastroenterology
How do you counsel a patient on returning to the care of their PCP when a workup for MCAS has been unrevealing, but the patient insists that they have a mast cell disorder because they respond to antihistamine therapy?
Related Questions
Is there a role for nitazoxanide for treatment of norovirus gastroenteritis in immunocompromised patients?
What is your approach to treatment of patients with fulminant C difficile infection who required ileostomy creation or colectomy?
Which colonic polyp or mass-like lesions do you refer to an advanced endoscopist?
Is there a role for anti-IL5 therapy in the treatment of EoE?
Under what circumstances would you recommend early fecal microbiota transplantation over antibiotic treatment or bezlotoxumab in a patient with recurrent C. difficile infection?
How do you approach managing nausea and GI side effects when initiating methotrexate?
How would you approach management of a patient with a medium-to-large vessel vasculitis who developed perforation of the stomach and colon on steroids and cyclophosphamide?
Has your institution and/or antimicrobial stewardship program incorporated a selective antibiotic approach to treatment of left-sided uncomplicated diverticulitis in immunocompetent patients?
Do you favor 24 hour urinary metabolites over random urine collection when screening for MCAS?
Do 5HT4 agonists such as Metoclopramide actually lead to improvement in symptoms for patients with diabetes related gastroparesis?
